# Altesa BioSciences

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/altesa-biosciences

- Industry: Biotechnology
- Headquarters: College Park, US
- Website: www.altesabio.com/
- Total disclosed funding: $4M
- Latest round: Seed (Feb 10, 2022)
- Investors on record: 1

## About

Based in Georgia, US, and founded in 2022 by George Painter, Dennis Liotta, Seth Rudnick, and John M. Clerici, Altesa BioSciences Inc. is a clinical-stage biopharmaceutical company that develops drugs for the treatment of RNA viruses that are highly responsible for viral diseases. In February 2026, Altesa BioSciences Inc. raised USD 75 million in series B funding from Forbion, Sanofi, Medicxi, and Atlantic Partners, Pitango.

Altesa BioSciences Inc. is under development stage of drugs to treat RNA viruses, including rhinovirus, influenza, respiratory syncytial virus (RSV), dengue virus, yellow fever virus, ebola virus, and SARS-CoV-2 (COVID-19). The company’s product ALT-2023 is in the early development stage, which shows the capability to treat yellow fever, dengue fever, and powassan virus.

Altesa BioSciences Inc. plans to use its proceeds from February 2022 funding to develop drugs for viral diseases.

## Funding rounds

- Seed, Feb 10, 2022, $4M — Pitango

## Investors

- Pitango (https://capitalatlas.ai/funds/pitango) — Seed